Table 3.
Association of TGF-β1 variants with OS, DSS, and DFS of SCCOP patients stratified by tumor HPV16 status
| Genotypes | OS | DSS | DFS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall death/ Total |
Log-rank P value |
aHRa (95% CI) | Death, owing to disease/ Total |
Log-rank P value |
aHRa (95% CI) | Recc./ Total |
Log- rank P value |
aHRa (95% CI) | |
| Tumor HPV-positive SCCOP patients (N = 482) | |||||||||
| TGF-β1 rs1800469 | 0.876 | 0.450 | 0.192 | ||||||
| CCb | 41/318 | 1.0 | 21/318 | 1.0 | 31/318 | 1.0 | |||
| CT + TT | 25/164 | 1.1(0.6–1.8) | 16/164 | 1.4(0.7–2.8) | 24/164 | 1.5(0.8–2.5) | |||
| TGF-β1 rs1982073 | < 0.001 | < 0.001 | < 0.001 | ||||||
| TTb | 39/155 | 1.0 | 26/155 | 1.0 | 35/155 | 1.0 | |||
| CT + CC | 27/327 | 0.1(0.1–0.3) | 11/327 | 0.1(0.1–0.3) | 20/327 | 0.2(0.1–0.3) | |||
| TGF-β1 rs1800471 | 0.496 | 0.600 | 0.234 | ||||||
| GGb | 48/376 | 1.0 | 26/376 | 1.0 | 36/376 | 1.0 | |||
| CG + CC | 18/106 | 0.8(0.5–1.5) | 11/106 | 0.9(0.4–1.8) | 19/106 | 1.4(0.8–2.6) | |||
| Tumor HPV-negative SCCOP patients (N = 82) | |||||||||
| TGF-β1 rs1800469 | 0.277 | 0.657 | 0.551 | ||||||
| CCb | 6/53 | 1.0 | 4/53 | 1.0 | 5/53 | 1.0 | |||
| CT + TT | 6/29 | 2.8(0.7–10.4) | 3/29 | 3.8(0.5–27.2) | 4/29 | 4.2(0.4–47.7) | |||
| TGF-β1 rs1982073 | 0.585 | 0.677 | 0.772 | ||||||
| TTb | 2/15 | 1.0 | 1/15 | 1.0 | 2/15 | 1.0 | |||
| CT + CC | 10/67 | 2.1(0.4–11.4) | 6/67 | 4.2(0.3–56.4) | 7/67 | 0.8(0.1–4.7) | |||
| TGF-β1 rs1800471 | 0.540 | 0.433 | 0.841 | ||||||
| GGb | 8/57 | 1.0 | 4/57 | 1.0 | 6/57 | 1.0 | |||
| CG + CC | 4/25 | 1.6(0.4–6.0) | 3/25 | 2.3(0.4–13.5) | 3/25 | 1.0(0.2–4.5) | |||
a
Hazard ratio adjusted for age, sex, ethnicity, alcohol use status, stage, comorbidity, and treatment.
b
Reference group.
c
Rec.: Recurrence